Strides Pharma Science Ltd Downgraded to Sell Amid Mixed Fundamentals and Technical Weakness

Technical Trends Signal Caution

The downgrade was primarily triggered by a shift in the technical grade from mildly bullish to sideways, signalling a loss of upward momentum in the stock price. Key technical indicators paint a mixed picture: the Moving Average Convergence Divergence (MACD) on both weekly and monthly charts remains mildly bearish, while the Relative Strength Index (RSI) is neutral on a weekly basis but bearish monthly. Bollinger Bands show a mildly bearish stance weekly but mildly bullish monthly, indicating short-term volatility with uncertain direction.

Other technical metrics such as the Know Sure Thing (KST) oscillator are mildly bearish on both weekly and monthly timeframes, and Dow Theory analysis reveals no clear trend. On-Balance Volume (OBV) also shows no discernible trend, suggesting a lack of strong buying or selling pressure. Daily moving averages remain mildly bullish, but this is insufficient to offset the broader sideways technical outlook.

These technical signals collectively suggest that the stock may face resistance in sustaining upward price movement in the near term, warranting a more cautious stance from investors.

Valuation Improves but Raises Questions

Interestingly, the valuation grade for Strides Pharma has improved from attractive to very attractive, reflecting a more compelling price point relative to earnings and enterprise value metrics. The company’s price-to-earnings (PE) ratio stands at 14.34, significantly lower than peers such as Ajanta Pharma (36.05) and Gland Pharma (34.38), indicating a discount valuation. Other valuation multiples include an EV/EBITDA of 10.54 and EV to capital employed of 2.18, both suggesting the stock is trading at a reasonable level compared to its operational earnings and asset base.

Return on Capital Employed (ROCE) is reported at 15.60%, and Return on Equity (ROE) at 15.82%, both healthy figures that support the valuation attractiveness. Dividend yield remains modest at 0.47%, consistent with the pharmaceutical sector’s typical payout patterns.

Despite this, the valuation improvement alone has not been sufficient to offset concerns arising from technical and fundamental trends, leading to the overall downgrade.

Financial Trend: Mixed Signals Amid Strong Quarterly Performance

Financially, Strides Pharma has delivered very positive quarterly results for Q3 FY25-26, with net profit growth of 133.64% and operating profit to interest coverage at a robust 5.44 times. The company has reported positive results for ten consecutive quarters, demonstrating operational resilience. The half-year ROCE peaked at 16.05%, underscoring efficient capital utilisation in the short term.

However, long-term financial trends reveal some weaknesses. The average ROCE over a longer horizon is a modest 7.27%, and net sales have grown at a compound annual rate of 9.32% over five years, with operating profit growth at 15.52%. These figures suggest moderate growth relative to sector peers. Additionally, the company’s debt servicing ability is a concern, with a high Debt to EBITDA ratio of 6.58 times, indicating elevated leverage and potential vulnerability in adverse market conditions.

Promoter shareholding also presents a risk factor, with 30.6% of promoter shares pledged. This can exert downward pressure on the stock price during market downturns, adding to investor caution.

Quality Assessment: Long-Term Fundamentals Under Pressure

While Strides Pharma has demonstrated strong short-term financial performance, its long-term fundamental strength is weaker. The company’s average ROCE of 7.27% over multiple years is below the threshold typically favoured by quality investors. Growth rates in sales and operating profit, though positive, are not sufficiently robust to inspire confidence in sustained expansion.

Moreover, the high debt levels and promoter pledge ratio detract from the company’s quality profile, increasing risk in volatile market environments. These factors contribute to the overall downgrade in the investment rating despite the company’s recent operational successes.

Stock Performance and Market Comparison

Strides Pharma’s stock price closed steady at ₹857.35 on 16 Feb 2026, unchanged from the previous day. The 52-week high and low stand at ₹1,024.90 and ₹551.00 respectively, indicating significant price volatility over the past year. The stock has underperformed the Sensex in the short term, with a one-week return of -3.16% compared to the Sensex’s -0.94%, and a one-month return of -4.81% versus -0.35% for the benchmark.

However, the stock has delivered impressive long-term returns, outperforming the Sensex by a wide margin over three and five years, with returns of 504.89% and 99.34% respectively, compared to 35.81% and 59.83% for the Sensex. This strong historical performance highlights the company’s growth potential but also underscores the need for caution given recent technical and fundamental shifts.

Conclusion: A Balanced Yet Cautious Outlook

Strides Pharma Science Ltd’s downgrade to a Sell rating reflects a nuanced assessment of its investment merits. While the company boasts a very attractive valuation and has delivered strong recent quarterly results, the technical indicators suggest a loss of bullish momentum. Long-term fundamental concerns, including moderate growth rates, high leverage, and significant promoter share pledging, further weigh on the stock’s outlook.

Investors should weigh the company’s impressive historical returns and valuation discount against the risks posed by its technical sideways trend and financial leverage. The downgrade signals a need for caution and suggests that alternative opportunities within the pharmaceuticals sector or broader market may offer superior risk-adjusted returns at this juncture.

Unlock special upgrade rates for a limited period. Start Saving Now →